<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04825522</url>
  </required_header>
  <id_info>
    <org_study_id>REB# 21-393</org_study_id>
    <nct_id>NCT04825522</nct_id>
  </id_info>
  <brief_title>The Effect of Intrawound Vancomycin Powder in Spine Surgery</brief_title>
  <official_title>The Effect of Intrawound Vancomycin Powder in Spine Surgery: A Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Windsor-Essex Compassionate Care Community</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Windsor-Essex Compassionate Care Community</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Problem: Postoperative wound infection following various spinal surgeries is a serious&#xD;
      complication. The incidence of post-surgical wounds in spine surgery is high, and various&#xD;
      researchers have reported different infection rates. In addition, increased healthcare costs,&#xD;
      prolonged lengths of stay in hospital, and reduced quality of life as a result of surgical&#xD;
      site infections (SSI) are also major concerns. Several methods for avoiding SSI, such as&#xD;
      betadine irrigation, vacuum-assisted closure, and intra-wound vancomycin powder, have been&#xD;
      used to reduce the rate of wound infection in spine surgery. Use of local vancomycin has been&#xD;
      popular because of its protective effects and lower cost. According to some reports,&#xD;
      prophylactic administration of intra-wound vancomycin powder before wound closure is an&#xD;
      effective method for decreasing postoperative wound infection rates; however, other studies&#xD;
      have revealed a non-significant effect of intra-wound vancomycin use for decreasing the&#xD;
      postsurgical wound infection rate.&#xD;
&#xD;
      Solution: Therefore, the investigators will prospectively randomize all various types of&#xD;
      spinal surgeries to patients who will receive intrawound vancomycin powder and control group&#xD;
      who will not receive the powder and to see it's effect in reducing the post-surgical&#xD;
      infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potential participants will be identified at the clinic, emergency department, or on the&#xD;
      floor by history, clinical examination, and positive imaging findings. The surgeon will&#xD;
      notify the study coordinator of the potential patient. The study coordinator will introduce&#xD;
      the trial to the patient and obtain informed consent at the office during the clinic visit or&#xD;
      his hospital stay. Patient's pre-operative data such as demographics (age and sex), presence&#xD;
      of comorbidities like diabetes, ischemic heart disease, asthma patients on steroids,&#xD;
      nutrition status using serum albumin level, and previous posterior spine surgical procedures&#xD;
      at the operative level will be collected once the patient admitted prior to the procedure.&#xD;
      The study coordinator will enroll the patient into the trial, and provide the appropriate&#xD;
      intervention (vancomycin application, or no application) using the closed envelope technique&#xD;
      of randomization to the neurosurgeon performing the procedure. Patients will also be blinded&#xD;
      to avoid the placebo effect. All patients will receive the standard systemic antibiotic&#xD;
      prophylaxis. The duration of the procedure, estimated blood loss, type of the procedure&#xD;
      (instrumented versus non-instrumented) and the number of levels will be recorded. After the&#xD;
      intervention, wound infections will be monitored during a follow-up period of 12 weeks from&#xD;
      the date of surgery. Cultured organisms and subsequent treatments will be recorded. The&#xD;
      primary outcome is the incidence of infection (either in-patient or in the follow-up). The&#xD;
      secondary outcome is the development of other complications including Vancomycin related.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Experimental Group: For surgeries involving one level, 500mg of vancomycin will be applied. For surgeries involving greater than 1 level and less than 3 levels, 1gm will be applied and for surgeries greater than 3 levels, 2gms will be applied.&#xD;
Control Group: Will not receive any extra treatment.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The patients will not know if they received vancomycin or not.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Infection</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients with post-operative wound infection after spinal surgery (including the type of organism and duration of the procedure). Investigators will prospectively randomize all various types of spinal surgeries to patients who will receive intrawound vancomycin powder and control group who will not receive the powder and to see it's effect in reducing the post-surgical infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients who developed any complications related to the vancomycin.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1643</enrollment>
  <condition>Spine Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will not be receiving vancomycin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For surgeries involving one level, 500mg of vancomycin will be applied. For surgeries involving greater than 1 level and less than 3 levels, 1gm will be applied and for surgeries greater than 3 levels, 2gms will be applied.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>During spinal surgery, participants will receive intrawound vancomycin powder in their wound before closure.</description>
    <arm_group_label>Vancomycin</arm_group_label>
    <other_name>Treatment group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients requiring surgery due to any spine disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A previous history of infections at the spine surgical site.&#xD;
&#xD;
          -  Biopsy procedure.&#xD;
&#xD;
          -  Patients with a postoperative follow-up time of less than 12 weeks.&#xD;
&#xD;
          -  Patients allergic to vancomycin.&#xD;
&#xD;
          -  Patient is less than 18 years old.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Soliman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Soliman, MSc, MD</last_name>
    <phone>+17329241637</phone>
    <email>msolim8@uwo.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdalla Shamisa, FRCSC</last_name>
    <phone>+12267875232</phone>
    <email>ashamisa@yahoo.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Windsor Regional Hospital - Ouellette</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N9A 1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdalla Shamisa, MD</last_name>
      <phone>519-973-8771</phone>
      <email>ashamisa@yahoo.ca</email>
    </contact>
    <contact_backup>
      <last_name>Balraj Jhawar, MD</last_name>
      <phone>519-973-8771</phone>
      <email>bsjahwar@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cairo University Hospitals</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noha Assem, MD</last_name>
      <phone>+201201730249</phone>
      <email>kasralainirec@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Helmy El-Dessouky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wael El Mahdy, MD, FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Xie LL, Zhu J, Yang MS, Yang CY, Luo SH, Xie Y, Pu D. Effect of Intra-wound Vancomycin for Spinal Surgery: A Systematic Review and Meta-analysis. Orthop Surg. 2017 Nov;9(4):350-358. doi: 10.1111/os.12356. Review.</citation>
    <PMID>29178308</PMID>
  </reference>
  <reference>
    <citation>Tomov M, Mitsunaga L, Durbin-Johnson B, Nallur D, Roberto R. Reducing surgical site infection in spinal surgery with betadine irrigation and intrawound vancomycin powder. Spine (Phila Pa 1976). 2015 Apr 1;40(7):491-9. doi: 10.1097/BRS.0000000000000789.</citation>
    <PMID>25608241</PMID>
  </reference>
  <reference>
    <citation>Evaniew N, Khan M, Drew B, Peterson D, Bhandari M, Ghert M. Intrawound vancomycin to prevent infections after spine surgery: a systematic review and meta-analysis. Eur Spine J. 2015 Mar;24(3):533-42. doi: 10.1007/s00586-014-3357-0. Epub 2014 May 18. Review.</citation>
    <PMID>24838506</PMID>
  </reference>
  <reference>
    <citation>Hey HWD, Thiam DW, Koh ZSD, Thambiah JS, Kumar N, Lau LL, Liu KG, Wong HK. Is Intraoperative Local Vancomycin Powder the Answer to Surgical Site Infections in Spine Surgery? Spine (Phila Pa 1976). 2017 Feb 15;42(4):267-274. doi: 10.1097/BRS.0000000000001710.</citation>
    <PMID>28207669</PMID>
  </reference>
  <reference>
    <citation>O'Neill KR, Smith JG, Abtahi AM, Archer KR, Spengler DM, McGirt MJ, Devin CJ. Reduced surgical site infections in patients undergoing posterior spinal stabilization of traumatic injuries using vancomycin powder. Spine J. 2011 Jul;11(7):641-6. doi: 10.1016/j.spinee.2011.04.025. Epub 2011 May 19.</citation>
    <PMID>21600853</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 28, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>April 24, 2021</last_update_submitted>
  <last_update_submitted_qc>April 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Windsor-Essex Compassionate Care Community</investigator_affiliation>
    <investigator_full_name>Mohamed Soliman</investigator_full_name>
    <investigator_title>Assistant Professor of Neurosurgery, General Neurosurgery Clinical Fellow, Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

